Fig. 7

Downregulation of exosomal miR-183-5p reduced the cardioprotective effects of Hemin-MSC-EXO. A Representative echocardiographic images 28 days after MI in mice that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. B The LVEF and LVFS were calculated at 28 days in mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. C Representative images of Masson’s trichrome staining of heart sections from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. Red, myocardium; blue, scarred fibrosis. D Quantitative analysis of infarct size in mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. E Representative images of SA-β-gal staining of heart tissue from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. F Quantitative analysis of SA-β-gal positive area in heart tissue from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. G Representative images of Troponin (red) and p21 (green) staining in heart tissue from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. H Quantitative analysis of Troponin⁺/p21⁺ double-positive cells in heart tissue from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. I Representative TEM images of mitochondria in heart tissue from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. J Quantitative analysis of mitochondrial fragmentation in heart tissue from mice with MI that received Hemin-MSC-EXO or miR-183-5p^KD-Hemin-MSC-EXO treatment. Data are expressed as mean ± SD. n = 6 mice for each group, ***p < 0.001